News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
GlobalData on MSN10h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...
WFYI1d
Senators raise questions about deals between telehealth and drug companies
Lawmakers warn the arrangement Eli Lilly and Pfizer have with telehealth platforms may lead to conflicts of interest, subpar ...
Trim Your AI Stocks And Buy Eli Lilly
AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...